Androxal 25 mg

DRUG3 trials

Sponsors

Repros Therapeutics Inc.

Conditions

PharmacokineticsSecondary Hypogonadism

Phase 1

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

CompletedNCT01923870

Repros Therapeutics Inc.Secondary Hypogonadism

Start: 2013-08-31End: 2014-01-31Updated: 2014-01-24

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

CompletedNCT01923857

Repros Therapeutics Inc.Secondary Hypogonadism

Start: 2013-08-31End: 2014-08-31Updated: 2014-08-11

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

CompletedNCT02169804

Repros Therapeutics Inc.Pharmacokinetics

Start: 2014-08-31End: 2014-08-31Updated: 2014-10-01